Heavy metals and ALS: what the evidence does (and doesn't) mean for you
- Richard Moore
- Jul 8
- 11 min read
In at least one documented case, a patient with clinical signs and electromyographic findings consistent with amyotrophic lateral sclerosis (ALS), and blood mercury levels that confirmed intoxication, was treated with chelation therapy using dimercaptosuccinic acid (DMSA). The metal burden fell. Her neurological course didn’t change (Praline et al., 2007).
That case is one of the more clinically useful data points in this field, not because it proves metals are irrelevant in ALS, but because it shows that removing them after the fact doesn't appear to change what's already happening.
There is also an important clinical distinction to make at the outset. Confirmed heavy-metal poisoning is a medical condition that needs proper assessment and should be managed by a doctor or toxicologist. That is a different situation from the ALS research discussed in this blog, where metal levels are being studied as possible risk markers, contributors or exposure signals. A raised result in an ALS context does not automatically mean chelation is appropriate, and it certainly doesn't mean chelation is an ALS treatment.
None of that makes the research linking metals to ALS any less important. If anything, it makes the question more interesting. If elevated levels of some metals are repeatedly found in ALS cohorts, yet removing them after diagnosis doesn't appear to change the course of the disease, then what is the evidence actually telling us, and what should someone living with ALS do with it?
The gap between a headline and what the science actually says
Part 1 of this series covered a striking finding: people with ALS were found to have higher levels of several metals and trace elements in their blood and urine than people without the disease, and combined exposure was linked to close to three times the odds of having the condition (Jang et al., 2025). That's the kind of result that travels well, a number, a comparison, a clear-looking signal.
What travels less well is what the number can and cannot tell you. The studies in Part 1 were observational. Researchers measured what was there, compared two groups, and found a pattern. They were not designed to prove that metals cause ALS. They were designed to ask whether a relationship exists, and they found that it does. That's real progress, and it's how good science starts. But the distance between "these things tend to appear together" and "one caused the other" is enormous, and it's exactly where patients and carers most need clarity.
Consider: in summer, ice cream sales rise. So does the number of deaths by drowning. The two track each other closely enough that you could draw a convincing graph. The missing variable is warm weather, which drives both independently (Lucas & McMichael, 2005). Nobody argues that ice cream causes drowning, but the correlation is still there.
ALS and metals face a version of this problem, and one that goes deeper than it first appears.
What if the disease is creating the evidence, not the other way around?
One of the most important and least-discussed questions in this field is whether elevated metals in people with ALS arrived before the disease, or because of it.
ALS involves widespread metabolic disruption, including changes to how the body generates energy, manages inflammation and clears waste. Some of these changes may begin years before a diagnosis is made (Vargas et al., 2023). The body's machinery for transporting, binding and excreting metals is part of that same disrupted system. So what shows up in a blood or urine sample taken from someone who already has ALS may partly reflect what the disease has done to their body's metal handling, rather than an exposure that came first and triggered it.
Researchers call this reverse causation. Think of the difference between a river flooding a town and floodwater carrying silt downstream. You'd find silt and flood together every time. But the silt didn't cause the flood, the flood moved the silt. With a single blood sample taken after diagnosis, you often can't tell which direction the story ran.
This is precisely why the childhood teeth study mentioned in Part 1 is so scientifically important (Figueroa-Romero et al., 2020). It measured metal patterns from early life, long before disease onset, which helps sidestep the reverse-causation problem. It's also why researchers are increasingly focused on prospective studies, ones that measure exposure before any diagnosis occurs and follow people forward, rather than only working backwards from a blood test.
What you did for thirty years may tell us more than what's in your blood today
The occupational evidence is where the science stands on firmer ground, and it's where one of the strongest signals in this area of research appears to live.
Occupational studies don't ask only what's in your blood today. They ask what you did for a living, across years, before you became unwell. Because the job came first and the diagnosis came later, the reverse-causation problem is substantially reduced.
A case-control study from the University of Michigan surveyed 381 people with ALS and 272 controls in depth about their working lives. Independent exposure scientists, who didn't know which participants had ALS, then assessed the likely chemical burden of those roles. When all occupational factors were analysed together, metal exposure remained the most consistent signal. People who had worked in manufacturing, welding and chemical operations carried a 56% higher odds of ALS, even after adjusting for age, sex and military service (Goutman et al., 2022). Particulate matter and pesticides also appeared in the data, but metal exposure was what held up most reliably under statistical pressure.
A separate study using the National ALS Registry found that people with ALS were more than twice as likely to have held jobs with documented lead exposure. Those with a history of both lead and agricultural chemical exposure had over seven times the odds of an ALS diagnosis compared with controls, one of the higher occupational risk figures reported in this literature (Taioli et al., 2021). The same study also found markedly elevated oxidative stress markers in ALS patients' blood, hinting at a possible biological pathway connecting decades-old exposure with what may be happening in cells now.
This is still not proof of causation. But when similar signals keep appearing across different countries, different study designs and different research groups, they deserve to be taken seriously.
A government that moved before the science could prove everything
Most people outside the ALS community do not know this: US military veterans appear to develop ALS at a higher rate than people who never served. According to the VA, studies show veterans are about 1.5 times more likely to develop ALS than those who never served (U.S. Department of Veterans Affairs, 2026), and some research suggests that risk may increase with total years served and certain types of service.
Military service, looked at through an environmental lens, can involve a heavy mixture of exposures: firing ranges, burn pits, engine exhaust, contaminated groundwater at certain bases, solvents and industrial chemicals. Veterans with ALS have been reported to have disproportionate exposure histories to herbicides, pesticides, certain metals and burning agents compared with civilian cases (Longatti et al., 2022).
What is telling: the United States Veterans Affairs system classifies ALS as a presumptive service-connected condition for qualifying veterans. In practical terms, veterans who develop ALS don't have to prove that their service caused it in order to access support. That decision was made by policy makers, not by a completed causal model. It doesn't prove that heavy metals cause ALS. But it represents an institutional judgement that the association between military service and ALS is strong enough to justify action, even while the exact exposures and mechanisms remain unresolved.
The science is still being cautious. The policy has already moved.
When the treatment didn't work - and why that still tells us something
Which brings us back to where we started.
When metal levels fall but ALS continues to progress, it suggests something important: by the point of diagnosis, whatever role elevated metals may have played, as a trigger, a contributor, a marker, or an accelerant, removing them from circulation doesn't appear to reverse established motor neurone degeneration. The disease has its own momentum by then. The window, if there ever was one, was almost certainly years earlier.
This does not mean metals were never involved. It means that trying to remove them after the fact, in someone already ill, has not been shown to help. That's a clinically important distinction.
It also means chelation carries risk without demonstrated benefit as an ALS treatment. The drugs used to bind and remove toxic metals don't only interact with lead or mercury, they may also affect essential minerals such as zinc, copper and selenium, whose balance is already part of the conversation in ALS research. Chelation can carry real medical risks, including kidney strain and dangerous shifts in mineral status. For someone with ALS, that is not a neutral trade-off.
The same caution applies to supplement-based "detox" protocols sold online, chlorella, activated charcoal, high-dose cilantro extract and the rest. None of these have been shown to treat ALS. Several can interfere with mineral balance, medication timing or nutrient absorption. They borrow the language of this research without being supported by it.
Where this body of evidence actually sits
In 1965, Austin Bradford Hill, one of the scientists who helped prove that smoking causes cancer, published a set of principles for judging whether an observed association is likely to be causal: strength of effect, consistency across studies, biological plausibility, and whether exposure reliably comes before disease. A systematic review applied that framework to more than 1,700 papers on environmental factors and ALS, and identified several heavy metals, including mercury, zinc, copper and manganese, as environmental determinants worth taking seriously (Newell et al., 2022). Not proven causes. Meaningful environmental determinants.
Against those criteria, the metals-and-ALS case has real strengths: a sizeable observational association, consistency across research groups and countries, and plausible biological mechanisms through oxidative stress, mitochondrial disruption and impaired metal handling. Where it remains weaker is temporality, we still need prospective studies that measure exposure before ALS begins and follow people forward. That's the gap the field is now actively working to close.
Researchers are also beginning to investigate whether genetic differences in the systems that transport, bind and clear metals might help explain why one person in an industrial workplace develops ALS and the person beside them doesn't (Goutman et al., 2023). If your body handles metals less efficiently than average, the same decades of exposure may not land in the same way. That work is still early, but it's exactly the kind of question that could eventually fill in what current evidence can't yet explain.
Before we get to what you can do - something needs to be said
Reading about metals and ALS when you have ALS, or when someone you love does, is not the same as reading about it out of curiosity.
You may already be asking the question underneath this whole blog, even if you haven't said it out loud: did what I was exposed to - the job, the water, the years in that building - have something to do with this?
This research cannot answer that for any one person. It cannot confirm that your exposure history caused your ALS, because causation hasn't been established. What it can say, and this is worth something, is that the connection you may sense between certain working lives, certain environments and a diagnosis like this is not irrational. The research is finding a signal there. You are not imagining a question worth asking.
It also does not mean you caused this. The metals implicated in this research are present in most people's bodies at some level. Most people exposed to them will never develop ALS. The fact that exposure may contribute to risk does not make it a decision you made. This is a disease that the world's leading neurologists still don't fully understand.
What this research does, and doesn't, mean for your decisions now
Chelation and detox protocols are off the table as ALS treatments. But ruling things out isn't the same as being left with nothing.
Reducing ongoing avoidable exposure, where it's practically within reach, is sensible, not because it changes a diagnosis, but because the research points repeatedly to cumulative lifetime exposure as the relevant variable. For most people this means proportionate steps: taking care during renovation of older buildings where lead-based paint may be present, being mindful of high-mercury fish eaten regularly, and seeking occupational health advice if still working in a role with meaningful metal exposure.
Mineral balance, zinc, copper and selenium, may also be worth considering, but in the right way. The concern isn't that these nutrients exist in the body. They're essential. The concern is dysregulation. Supplementing without testing is not the answer. Assessing what's actually there and responding to what the results show is something different, and belongs in a conversation with a practitioner who understands both the nutritional science and the context of ALS and motor neurone disease (MND).
For anyone still searching for something to hold onto: the fact that serious, well-funded research is finding consistent environmental and occupational signals in ALS is worth something real. For decades, the disease was often spoken about as though it were almost entirely genetic, random or simply unexplained. That picture is changing. The questions that feel important to patients and families are being taken seriously by researchers. That counts for something, even when the answers aren't complete yet.
How You Nutrition Clinic can help
Living with ALS, or caring for someone who does, means constantly filtering information, some of it useful, much of it overstated, and almost none of it written with any understanding of how hard it is to read.
At You Nutrition Clinic, our role is not to promise what nutrition cannot deliver, but to be precise about what it can. We assess mineral status, support antioxidant defences through food-first strategies, identify avoidable exposure risks where relevant, and work alongside your medical team throughout. Our dedicated MND/ALS programme, No Stone Unturned, is led by Dr Kirstie Lawton and supports people at every stage, from early symptoms through to advanced disease.
You can find out more at younutritionclinic.com/mnd or contact the clinic at admin@younutritionclinic.com.
🧩 Connect with us
For research updates, practical tips, and ongoing inspiration, follow us on Instagram:
Stay curious. Stay hopeful. Support your brain. 🧠
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult with a qualified, registered medical doctor (MD) for diagnosis and treatment decisions.
References
Figueroa-Romero, C., Mikhail, K. A., Gennings, C., Curtin, P., Bello, G. A., Botero, T. M., Goutman, S. A., Feldman, E. L., Arora, M., & Austin, C. (2020). Early life metal dysregulation in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 7(6), 872–882. https://doi.org/10.1002/acn3.51006
Goutman, S. A., Boss, J., Godwin, C., Mukherjee, B., Feldman, E. L., & Batterman, S. A. (2022). Associations of self-reported occupational exposures and settings to ALS: A case-control study. International Archives of Occupational and Environmental Health, 95(8), 1759–1772. https://doi.org/10.1007/s00420-022-01874-4
Goutman, S. A., Savelieff, M. G., Jang, D. G., Hur, J., & Feldman, E. L. (2023). The amyotrophic lateral sclerosis exposome: Recent advances and future directions. Nature Reviews Neurology, 19(10), 617–634. https://doi.org/10.1038/s41582-023-00867-2
Jang, D. G., Dou, J. F., Koubek, E. J., Teener, S., Zhou, L., Bakulski, K. M., Mukherjee, B., Batterman, S. A., Feldman, E. L., & Goutman, S. A. (2025). Multiple metal exposures associate with higher amyotrophic lateral sclerosis risk and mortality independent of genetic risk and correlate to self-reported exposures: A case-control study. Journal of Neurology, Neurosurgery & Psychiatry, 96(4), 329–339. https://doi.org/10.1136/jnnp-2024-333978
Longatti, A., Manzoni, C., Lucchini, R., Lewis, P. A., Costagliola, G., & Ceccanti, M. (2022). A perspective on persistent toxicants in veterans and amyotrophic lateral sclerosis: Identifying exposures determining higher ALS risk. Journal of Neurology, 269(6), 2876–2889. https://doi.org/10.1007/s00415-021-10928-5
Lucas, R. M., & McMichael, A. J. (2005). Association or causation: Evaluating links between "environment and disease." Bulletin of the World Health Organization, 83(10), 792–795. https://doi.org/10.2471/blt.05.025353
Newell, M. E., Adhikari, S., & Halden, R. U. (2022). Systematic and state-of-the-science review of the role of environmental factors in amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease. Science of the Total Environment, 817, 152504. https://doi.org/10.1016/j.scitotenv.2021.152504
Praline, J., Guennoc, A.-M., Limousin, N., Hallak, H., de Toffol, B., & Corcia, P. (2007). ALS and mercury intoxication: A relationship? Revue Neurologique, 163(10), 1052–1056. https://doi.org/10.1016/j.neurol.2007.07.004
Taioli, E., Ragin, C., Moline, J., Landrigan, P. J., & Todd, A. C. (2021). Case-control study in ALS using the National ALS Registry: Lead and agricultural chemicals are potential risk factors. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 23(1–2), 93–100. https://doi.org/10.1080/21678421.2021.1936556
U.S. Department of Veterans Affairs. (2026). VA ALS system of care. https://www.va.gov/health/als.asp
Vargas, M. R., Johnson, D. A., & Johnson, J. A. (2023). Metabolic dysfunction in amyotrophic lateral sclerosis: A review of recent evidence. International Journal of Molecular Sciences, 24(9), 8193. https://doi.org/10.3390/ijms24098193
Comments